Linking inflammation and hypoxia to disease subtype and course in systemic sclerosis by exploratory analysis of SMAD-linker domains study

Linking inflammation and hypoxia to disease subtype and course in systemic sclerosis by exploratory analysis of SMAD-linker domains study - LISS

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON43179

Enrollment

Registered

2016-08-30

Start date

2016-11-15

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

systemic sclerosis - scleroderma

Interventions

linker

prognosis

SMAD

systemic sclerosis

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: -10 patients with limited systemic sclerosis (SSc), 10 with early diffuse SSc, 10 with established diffuse SSc without severe vasculopathy, 10 with established diffuse SSc with severe vasculopathy. -18 years or older

Exclusion criteria

Exclusion criteria: active inflammatory or infectious co-morbid disease

Design outcomes

Primary

Measure	Time frame
Amount of activated SMAD proteins in fibroblasts	—

Secondary

Measure	Time frame
effect of SMAD inhibitors on fibroblast activation. activation of other SMAD activating kinases.	—

Countries

The Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)